After recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open a diabetes research center in China in the second half of 2011, further ramping up the drugmaker’s presence in the world’s fastest-growing pharmaceutical market.
Five Indiana doctors made the list of drug-company favorites in a recent report by New York-based ProPublica. Carmel psychiatrist Chris Bojrab pulled in nearly $160,000, with the lion’s share coming from Indianapolis-based Eli Lilly and Co. and its antidepressant Cymbalta. Lafayette allergist Ketan Sheth was a close second, earning $159,225 from United Kingdom-based GlaxoSmithKline plc. Other doctors on ProPublica’s list: Indianapolis hematologist Maureen A. Cooper, who made $140,000, mostly from Cephalon; Terre Haute endocrinologist Isaiah Pittman, $126,000 mostly from Lilly; and Zionsville family physician Daniel Lynn Shull took home $102,000, nearly all of it from Lilly. After Lilly started disclosing its payments to doctors last year, Bojrab defended the pay for speaking on behalf of drug companies as well-earned. “We’re certainly well-compensated for what we do,” he said, adding that the pay is about 20-percent higher than what he would earn seeing patients. But it also requires a fair bit of work, especially arranging travel details. “It’s not uncommon for me to come home and spend three or four hours a night, just to work out the travel details,” he said. “And it’s not like the work that you had to do goes away.”
St. Francis Hospital & Health Centers has acquired the Immediate Care Centers' four Indianapolis-area locations: 1001 N. Madison Ave., 650 N. Girls School Road, 860 E. 86th St. and 992 N. Mitthoeffer Road. The centers were launched in 1981 by Bloomington-based Unity Physician Group. About 100,000 patients visit the centers each year. St. Francis, whose parent organization is based in Mishawaka, is the fourth-largest hospital system in the Indianapolis area.
A new professional service center on the northwest side of Indianapolis will employ 500 people to support the 70 hospitals operated by St. Louis-based Ascension Health. The Catholic not-for-profit organization is the parent of Indianapolis-based hospital system St. Vincent Health, which operates 19 hospitals around Indiana, including its flaghship campus on West 86th Street. St. Vincent employs more than 13,000 Hoosiers. The $10.9 million center is expected to open next summer and ramp up to peak employment by 2013. To lure the investment, the Indiana Economic Development Corp. offered Ascension up to $5 million in performance-based tax credits and up to $90,000 in training grants based on the company's job-creation plans. Develop Indy and the city of Indianapolis offered Ascension Health infrastructure support and a training grant worth up to $300,000. Develop Indy also will support a property-tax-abatement request before the Metropolitan Development Commission.
Orthopedic implant maker Zimmer Holdings Inc. saw its third-quarter profit climb 27 percent on lower operating expenses. The results beat Wall Street estimates, but Zimmer cut its estimate for revenue growth. The Warsaw-based company reported net income of $191.1 million, or 96 cents per share, up from $149.9 million, or 70 cents per share, a year ago. Sales fell 1 percent to $965 million. Analysts polled by Thomson Reuters expected, on average, earnings of 95 cents per share on $994.7 million in revenue. Zimmer narrowed its full-year profit forecast to a range of $4.24 to $4.29 per share. The company had previously set full-year expectations for profit between $4.15 and $4.35 per share. It also trimmed its estimate of revenue growth on a constant currency basis for the year to 2 percent versus an earlier projection of 3-percent to 5-percent growth.
Indianapolis-based Dow AgroSciences improved revenue during the third quarter, thanks to a 26-percent increase in volume, but it still recorded a loss for the period. The unit of Michigan-based Dow Chemical Co. on Thursday reported revenue of $948 million, up 19 percent from the same period last year, despite lower prices. Quarterly earnings before interest, taxes, depreciation and amortization, however, were a loss of $12 million—compared with a profit of $5 million a year ago. Dow Agro’s selling, general and administrative expenses increased 9 percent during the quarter because of new product launches and commercial activities related to recent seed acquisitions, the company said. Its research and development costs were up 14 percent.
The daughter of former Indianapolis Star publisher Eugene S. Pulliam keeps busy with a broad slate of local and international philanthropic efforts focused on everything from conservation to investigative reporting.
As senior vice president of human resources for Eli Lilly and Co., Mahony is the company’s senior-most leader responsible for the firm’s efforts to expand diversity.
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
Without an appeal, generic drugs are now poised to wipe away most of Lilly’s $750 million in annual U.S. revenue from Gemzar.
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
Local leaders are encouraging The Oaks Academy to duplicate its successful urban private school model at a second location as part of the massive investment in near-east-side redevelopment spurred on by Indianapolis’ successful bid for the 2012 Super Bowl.
Venture funds nationwide crested at $100 billion in 2000, but that number last year had drooped to $18 billion.
J.C. Hart Co. spent more than a year securing a $5 million bank loan to expand an existing project; Buckingham Cos. turned to the city to finance its ambitious project just north of the Eli Lilly and Co. campus.
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
The position at United Way of Central Indiana had been vacant because of budget issues.
Indiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched a website that aims to keep that talent in the state.
IU Hospital soon will receive the catchy new name Indiana University Health University Hospital as part of Clarian Health’s 2011 name change to Indiana University Health. Clarian announced new names for all 17 of its hospitals on Tuesday, saying the names would change in early 2011. Methodist Hospital, for example, will be called Indiana University Health Methodist Hospital—at least inside the halls of Clarian’s offices. Outside it? That’s hard to say. The only hospital that won’t get the “IU Health” tag added before its name is Riley Hospital for Children, which will be known as Riley Hospital for Children at Indiana University Health.
A new estimate has lowered the expected cost of the federal health care overhaul to Indiana's state government to perhaps $2.6 billion over the next decade — $1 billion less than an initial projection made last spring, according to the Associated Press. Robert Damler of the Seattle-based actuarial consulting firm Milliman Inc. told the state's Medicaid oversight commission on Monday that new information provided by the federal government will drop the possible costs an additional $330 million. The firm in May had lowered its initial estimate to $2.9 billion. The latest change is because the Centers for Medicare and Medicaid Services in late September changed its interpretation of the law regarding a prescription rebate program. In spite of Democratic criticism, Damler declined to remove an estimated $600 million in costs from the report that could come as a result of increased physician reimbursements.
Analysts think Eli Lilly and Co. may try to acquire its partner, San Diego-based Amylin Pharmaceuticals Inc., or chase companies with more approved products to offset repeated setbacks in bringing its pipeline drugs to market, reported Bloomberg News. From Amylin, Indianapolis-based Lilly would gain full control of the diabetes drug Byetta and a longer-acting version called Bydureon that was delayed last week by U.S. regulators. Another option for Lilly would be to build on its painkiller products, such as Cymbalta, by acquiring Pennsylvania-based Cephalon Inc. or Newark, N.J.-based Endo Pharmaceuticals Inc. By 2013, Lilly loses patents on medicines responsible for nearly half its revenue.
Indianapolis-based Home Health Depot Inc. said on Thursday it has acquired the Home Health Care Products LLC subsidiary of Arcadia Resources Inc., also headquartered here. Terms of the deal were not disclosed. Home Health Care Products sells mobility tools, respiratory devices, bathroom-safety and home-modification products, as well as daily living aids. Home Health Depot was founded in 1998 and purchased by CEO David Hartley in 2004. It has grown from a single office in Greenwood to 12 locations in Indiana and Illinois—increasing annual revenue from $300,000 to more than $6.7 million. The company has more than 100 employees.
OrthoIndy opened a new branch of its Indiana Orthopaedic Hospital in Greenwood. It will serve as a practice location for 21 physicians. Outpatient surgeries will begin in spring 2011. The new location will effectively replace OrthoIndy’s offices at the St. Francis Indianapolis Hospital near Interstate 65 and Emerson Avenue. St. Francis has sued some of the doctors involved in the new OrthoIndy location for breach of contract.
Eli Lilly and Co., under pressure to gain new products after setbacks this month with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc.
The Hancock County community is drawing interest because of recent hiring in the area and a strong population of seniors.
CEO John Lechleiter claims Eli Lilly and Co. isn’t interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
Wall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
The Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
Eli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage study, the second setback for a Lilly diabetes drug candidate in two days.
